The Role of Renin-Angiotensin System in Diabetic Nephropathy: An Update
Authors:
- Andre SanglardASAndre Sanglard
- Barbara Castello Branco MirandaBMBarbara Castello Branco Miranda
- Ana Luiza França VieiraAVAna Luiza França Vieira
- Marcus Vinicius Miranda MacedoMMMarcus Vinicius Miranda Macedo
- Rodrigo Lara SantosRSRodrigo Lara Santos
- Alexia Stenner Rodrigues Radicchi CamposACAlexia Stenner Rodrigues Radicchi Campos
- Amanda Campos PivaAPAmanda Campos Piva
- Ana Cristina Simoes e SilvaASAna Cristina Simoes e Silva
- 1 May 2025
- journal article
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 25 (8) , 591-600
Abstract
Background and Aims: Diabetic nephropathy (DN) is an important complication of diabetes, leading to end-stage renal disease (ESRD) worldwide. This review aimed to explore the role of the renin-angiotensin system (RAS) in DN, highlighting current treatments and emerging therapeutic perspectives. Methods: We conducted a narrative review of the literature up to March 2024, focusing on the classical and alternative RAS axes, their implications in DN, and novel therapeutic approaches. Data were sourced from Scopus, PubMed, Scielo, and Cochrane databases. Results: The classical RAS axis, involving angiotensin-converting enzyme (ACE), Angiotensin II (Ang II), and the AT1 receptor, promotes vasoconstriction, sodium retention, and fibrosis in DN. Hyperglycemia-induced Ang II increases oxidative stress, contributing to glomerular hyperfiltration and kidney damage. Current treatments include ACE inhibitors and angiotensin receptor blockers (ARBs), which reduce blood pressure and proteinuria, delaying DN progression. In contrast, the alternative RAS axis, featuring ACE2, Ang-(1-7), and the Mas receptor, offers renoprotective effects by counteracting Ang II actions. Ang-(1-7) reduces inflammation, fibrosis, and podocyte apoptosis. ACE2 activators, Ang-(1-7), and Mas receptor agonists show promise in preclinical studies, reducing glomerular fibrosis and improving renal function. Ang-(1-9) and alamandine may also hold potential in future treatments. Emerging therapies, such as the SGLT2 inhibitors, also demonstrate benefits in reducing DN progression. Conclusion: While ACE inhibitors, ARBs, and SGLT2 inhibitors remain central to DN management, the ACE2-Ang-(1-7)-Mas axis presents a promising therapeutic target. Future research should focus on translating preclinical findings into clinical applications, potentially improving DN treatment.Keywords
This publication has 78 references indexed in Scilit:
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseKidney International, 2022
- Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical ConsiderationsKidney International Reports, 2022
- 2020 update on the renin–angiotensin–aldosterone system in pediatric kidney disease and its interactions with coronavirusPediatric Nephrology, 2020
- Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!2020
- Mesenchymal stem cells modified with angiotensin-converting enzyme 2 are superior for amelioration of glomerular fibrosis in diabetic nephropathyDiabetes Research and Clinical Practice, 2020
- Diabetic Nephropathy: An Overview2019
- Impact of the AT2 Receptor Agonist C21 on Blood Pressure and BeyondCurrent Hypertension Reports, 2012
- Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular DysfunctionArchives of internal medicine (1960), 2007
- The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigmDiabetologia, 2002
- A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11Life Sciences, 1993